Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

117.98USD
22 May 2019
Change (% chg)

-- (--)
Prev Close
$117.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,904,142
52-wk High
$132.12
52-wk Low
$81.65

About

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.... (more)

Overall

Beta: 0.26
Market Cap(Mil.): $114,538.60
Shares Outstanding(Mil.): 970.83
Dividend: 0.64
Yield (%): 2.19

Financials

  LLY.N Industry Sector
P/E (TTM): 43.52 30.96 35.38
EPS (TTM): 2.71 -- --
ROI: 9.26 12.01 11.72
ROE: 32.35 13.30 16.38

Eli Lilly misses estimates for top-selling diabetes drug Trulicity, shares slip

Eli Lilly and Co on Tuesday reported lower-than-expected first-quarter sales for its top-selling diabetes drug Trulicity, and the U.S. drugmaker said the need to offer rebates and discounts were taking a toll and likely to weigh on revenue growth for the year.

Apr 30 2019

Eli Lilly quarterly profit more than triples on Elanco gain

April 30 Eli Lilly and Co's first-quarter profit more than tripled, as the U.S. drugmaker recorded a $3.7 billion gain from its spin-off of animal health unit Elanco.

Apr 30 2019

Lower dose of Pfizer-Lilly painkiller misses main goals in late stage study

A lower dose of non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis of the hip or knee, the companies said on Thursday.

Apr 18 2019

Lower dose of Pfizer-Lilly painkiller misses main goals in late stage study

April 18 A lower dose of non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis of the hip or knee, the companies said on Thursday.

Apr 18 2019

Astellas, Eli Lilly must face lawsuit alleging underpaid Medicaid rebates

Astellas Pharma and Eli Lilly and Co must face a whistleblower lawsuit accusing them of knowingly underpaying rebates they owed to state Medicaid programs, a federal judge has ruled.

Apr 04 2019

Eli Lilly seeks to quell drug price anger with cheaper insulin

Drugmaker Eli Lilly announced plans on Monday to sell a half-price version of its popular insulin injection Humalog, as it fends off criticism about rising drug prices in the United States.

Mar 04 2019

Lilly to introduce lower-priced insulin injection

March 4 U.S. drugmaker Eli Lilly and Co said on Monday it would introduce a generic version of its Humalog insulin injection at a 50 percent lower list price than previous versions.

Mar 04 2019

Pfizer-Lilly drug shown to help reduce back pain in late-stage trial

A non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co succeeded in reducing chronic low back pain when used in a stronger dose, results from a late-stage study showed on Tuesday.

Feb 19 2019

Higher dose of Pfizer-Lilly drug helps reduce back pain in study

Feb 19 Pfizer and Eli Lilly said on Tuesday that a higher dose of their non-opioid drug tanezumab succeeded in reducing chronic low back pain in patients in a late-stage clinical study.

Feb 19 2019

RPT-German stocks - Factors to watch on Feb. 18

BERLIN/FRANKFURT, Feb 18 The following are some of the factors that may move German stocks on Monday:

Feb 18 2019

Earnings vs. Estimates